Third patient implanted with Ventracor device
Thursday, 23 October, 2003
Ventracor (ASX: VCR) has implanted its "artificial heart" device into a third patient as part of the pilot trial being conducted at the Alfred Hospital in Melbourne.
According to the chief medical investigator Prof Don Esmore, the patient is in a critical but stable condition.
He said the patient was gravely ill at the time of the procedure, and the implant was the only option available.
The announcement comes a couple of weeks after the second patient to receive the implant was discharged from hospital. The company plans to test up to ten patients in the pilot trial, before embarking on a larger, international trial.
Ventracor's share price rose four per cent yesterday after the announcement was made to close at AUD$2.49.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
